Emerging Endoscopic Therapies for Weight Loss
The prevalence of obesity and metabolic disease continues to rise in the United States and around the world. Efforts to combat this growing pandemic have utilized a multipronged strategy, including promoting public education, implementing public health measures, and focusing on a multidisciplinary treatment approach integrating nutrition, psychology, medicine, and surgery. Another component of this multipronged strategy has been the development of endoscopic therapeutic options less invasive than surgery. Currently, there are four FDA-approved devices, including three intra-gastric balloons and an aspiration device, which are discussed in a prior chapter. This chapter will focus on emerging endoscopic interventions for weight loss and metabolic therapies currently in development and/or undergoing clinical trials.
KeywordsEndoscopic devices Bariatric therapy Weight loss Metabolic disease Non-FDA-approved devices Gastroduodenal implant Malabsorptive sleeve Gastric motility Intestinal alterations
- 1.National Center for Health Statistics. National Health and Nutrition Examination Survey. 2014. URL: http://www.cdc.gov/nchs/nhanes.htm [accessed 2014-09-08][WebCite Cache]. 2014.
- 4.Ma IT, Madura JA. Gastrointestinal complications after bariatric surgery. Gastroenterol Hepatol. 2015;11(8):526.Google Scholar
- 7.Densford F. BaroNova touts TransPyloric Shuttle pivotal study data. In: MassDevice Medical Network. 2018. https://www.massdevice.com/baronova-touts-transpyloric-shuttle-pivotal-study-data/. Accessed 21 July 2019.
- 8.Densford F. BaroNova wins FDA nod for TransPyloric Shuttle weight loss device. In: MassDevice Medical Network. 2019. https://www.massdevice.com/baronova-wins-fda-nod-for-transpyloric-shuttle-weight-loss-device/. Accessed 21 July 2019.
- 9.Sauer N, Rösch T, Pezold J, Reining F, Anders M, Groth S, Schachschal G, Mann O, Aberle J. A new endoscopically implantable device (SatiSphere) for treatment of obesity—efficacy, safety, and metabolic effects on glucose, insulin, and GLP-1 levels. Obes Surg. 2013;23(11):1727–33.CrossRefGoogle Scholar
- 10.Gersin KS, Rothstein RI, Rosenthal RJ, Stefanidis D, Deal SE, Kuwada TS, Laycock W, Adrales G, Vassiliou M, Szomstein S, Heller S. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc. 2010;71(6):976–82.CrossRefGoogle Scholar
- 13.Sen Gupta P, Drummond RS, Lugg ST, McGowan BM, Amiel SA, Ryder RE. One year efficacy, safety and tolerability outcomes of endoscopic duodenal exclusion using EndoBarrier as an adjunct to glucagon-like peptide-1 (GLP-1) therapy in suboptimally controlled type 2 diabetes: a randomised controlled trial. In Novel treatment for diabetes-focusing on GLP-1 and SGLT2. Endocrine Society; 2016. p. PP15–PP11. https://onlinelibrary.wiley.com/page/journal/14631326/homepage/editorialboard.html.
- 15.Safety and efficacy of EndoBarrier in subjects with type 2 diabetes who are obese. In: ClinicalTrials.gov. 2016. https://clinicaltrials.gov/ct2/show/study/NCT01728116. Accessed 22 Oct 2017.
- 19.Lacy BE, Weiser K, Kennedy A. Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future? Gastroenterol Hepatol. 2008;4(4):283.Google Scholar
- 21.Foschi D, Corsi F, Lazzaroni M, Sangaletti O, Riva P, La Tartara G, Bevilacqua M, Osio M, Alciati A, Bianchi Porro G, Trabucchi E. Treatment of morbid obesity by intraparietogastric administration of botulinum toxin: a randomized, double-blind, controlled study. Int J Obes. 2007;31(4):707.CrossRefGoogle Scholar
- 28.Rajagopalan H, Cherrington AD, Thompson CC, Kaplan LM, Rubino F, Mingrone G, Becerra P, Rodriguez P, Vignolo P, Caplan J, Rodriguez L. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care. 2016;39(12):2254–61.CrossRefGoogle Scholar
- 34.Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913–6.CrossRefGoogle Scholar
- 35.Transplantation of microbes for treatment of metabolic syndrome & NAFLD. In: ClinicalTrials.gov. 2016. https://clinicaltrials.gov/ct2/show/results/NCT02496390. Accessed 22 Oct 2017.
- 38.Fecal microbiota transplant for obesity and metabolism. In: ClinicalTrials.gov. 2017. https://clinicaltrials.gov/ct2/show/study/NCT02530385. Accessed 22 Oct 2017.